Offering its product scope to more than 60 countries from Germany to Japan, Brazil to South Korea, Spain to South Africa, VSY Biotechnology is still going on to take part in most of the world’s most important congresses. VSY Biotechnology participated in DOC 2019 which was held in Germany, Nuremberg Convention Center between May 23-25,
VSY Biotechnology announced the launch of its new sinusoidal trifocal IOL, AcrivaUD Trinova, at the 2017 European Society of Cataract and Refractive Surgeons meeting in Portugal. VSY has also confirmed that its patent applications have been submitted around the world, and its product CE mark was received in October 2017. AcrivaUD Trinova is the world’s first and only sinusoidal trifocal IOL manufactured with Sinusoidal Vision Technology (SVT).
VSY Biotechnology BV and Carl Zeiss Meditec AG jointly announced that both companies resolved their legal and patent disputes with respect to Tri-ED 611. The companies agreed not to disclose the terms of the settlement.
CEO Özge Altunbaş Göktekin of VSY Biotechnology, a significant global company in the field of ophthalmology, gave us valuable information on cataract disease and solutions provided by the company’s new trifocal intraocular lenses. Altunbaş said: “With the help of the trifocal intraocular lenses we developed, we can offer a solution for both cataracts and eye defects.
VSY Biotechnology CEO Özge Altunbaş Göktekin stated that extraordinary developments observed recently in science and communication technologies have caused a transformation in the management approaches adopted by companies and added: “With technological advances transforming management ideas and approaches in enterprises, managers and employees now feel obliged to adopt a proactive, creative, and responsible role in their organization.”
We addressed our questions to VSY Biotechnology CEO Özge Altunbaş Göktekin about changing management approaches.
Presented at the ESCRS Satellite Symposium
VSY Biotechnology Offers “A New Approach to Trifocal Intraocular Lens Technology”
The European Cataract and Refractive Surgery Association held their 36th annual meeting from September 22nd to 26th, 2018. This meeting included an examination of trifocal intraocular lenses (IOLs) produced with advanced technology. Specifically, VSY Biotechnology shared the features and clinical results of AcrivaUD Trinova IOLs that they developed after extensive R&D studies.
The 36th ESCRS Congress will be organized by the European Cataract and Refractive Surgery Association in Wien/Austria on 22-26 September 2018. The Congress will enjoy the participation of international companies specialized in eye health who will present the latest innovations in the science of ophthalmology. While more than 10.000 visitors from all around the world are expected to attend the congress,
VSY Biotechnology took out a patent for a “Rotaryjet Preloaded Injector” enabling the easy, quick, and safe injection and implantation of intra-ocular lenses during cataract operations. The firm also became the owner of a patent for its new packing of intra-ocular lenses produced with biocompatible material that has strong sterilization characteristics.
In the “Rotaryjet Preloaded Injector,” which was invented and patented by VSY Biotechnology,
Osteoarthritis causes reduced movement and pain due to the disruption of the cartilaginous structures on the joint surface. New solutions offer treatments without surgery. One of the most important treatments recently accepted all over the world is intra-articular injection, which slows the progression of osteoarthritis.
Knee, hip, ankle, finger, and spinal joints are the sites in the body most commonly affected by osteoarthritis,
Over past eight years, 3 million people have been implanted VSY Biotechnology intraocular lenses through cataract surgeries, says CEO Ozge Altunbas Goktekin
Acriva Trinova lenses not only manage cataract, but also provides continuous sight on near, mid, far and intermediate ranges, CEO of the Netherlands based company VSY Biotechnology said.